New study tracks how kids with arthritis fare on Long-Term secukinumab
NCT ID NCT07190053
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 100 children aged 6 to 17 with juvenile psoriatic or enthesitis-related arthritis who are taking secukinumab. Researchers will observe how doctors adjust treatment after the disease becomes inactive, and whether patients experience flares. The goal is to learn the best long-term strategies for managing these conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- secukinumab
- What this could lead to
- If successful, this study could help doctors understand the best long-term strategies for managing juvenile arthritis with secukinumab, potentially reducing flares and medication burden.
- What could go wrong
- This is an observational study, not a controlled trial, so results may not prove cause and effect. It is also small (100 participants) and only includes children from Germany, limiting generalizability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENTHESITIS-RELATED ARTHRITIS (ERA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.